Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

133%

4 of 3 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

N/A

5(71.4%)

Phase 1

1(14.3%)

Phase 2

1(14.3%)

7Total

N/A(5)

Phase 1(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06238609Not ApplicableActive Not Recruiting

Neuromodulation for Prevention of Intensive Care Unit Acquired Weakness and Post Intensive Care Syndrome

Role: collaborator

NCT05198466Phase 2Completed

Electrical Stimulation for Critically Ill Post-Covid-19 Patients

Role: collaborator

NCT04685213Phase 1Completed

Electrical Stimulation for Critically Ill Covid-19 Patients

Role: collaborator

NCT03821675Not ApplicableCompleted

Electrical Stimulation to Accelerate Wound Healing

Role: collaborator

NCT03843307Not ApplicableTerminated

Avazzia-University of Texas Southwestern Medical Center-Tennant Biomodulator® PRO Perfusion Study

Role: lead

NCT04271319Not ApplicableUnknown

Avazzia HVPC Bio-Electrical Stimulation Technology (BEST™) Microcurrent CTS RCT

Role: lead

NCT04698733Not ApplicableUnknown

Veteran Affairs Osteoarthritis Knee Study

Role: lead

All 7 trials loaded